In this study, high levels of GPC4 were shown to be associated with longer relapse-free time in unclassified breast cancer, whereas in estrogen receptor negative and HER2-positive breast cancer low GPC4 levels led to a longer relapse-free time [42]. Here, ERBB2 is linked to breast carcinoma.